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Microcystic adnexal carcinoma (MAC) is an uncommon, locally aggressive, malignant cutaneous tumor with pilar and eccrine dif-
ferentiation. In this article we describe the clinical presentation, pathologic hallmarks, and the use of new adjunct diagnostic devices,
to optimize diagnosis, management and treatment options.
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Microcystic adnexal carcinoma (MAC) is an uncom-
mon, malignant adnexal neoplasm (Thomas et al., 2007).
There was a considerable debate regarding the appropriate
nomenclature of MACs. It was known as malignant syrin-
goma and syringoid carcinoma (Weedon, 2002), but those
terms are now used to describe either tumors with histolog-
ical features of MACs or higher grade malignancies with
the potential for metastatic spread (Sebastien et al.,behalf of King Saud University.
commons.org/licenses/by-nc-nd/4.0/).
Figure 1. MAC on the left upper lip of an elderly woman. Note the close clinical resemblance to basal cell carcinoma.
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gland cancer (Thomas et al., 2007).
MAC was ﬁrst described as a distinct clinico-pathologic
entity by Goldstein in 1982 (Goldstein and Barr, 1982). It is
a tumor with pilar and eccrine diﬀerentiation (Goldstein
and Barr, 1982); however it is locally aggressive, deeply
inﬁltrative and can invade bone, muscle, blood vessels,
cartilage and nerves, despite which the metastatic potential
is rare (Chiller et al., 2000).
Histological overlap with other benign and malignant
cutaneous proliferations makes diagnosis of MAC chal-
lenging, due to its infrequent occurrence. It is characterized
by keratin-ﬁlled cysts, nests, and cords of basaloid cells,
and by the formation of ductal structures within a desmo-
plastic stroma. This increase in stromal collagen is not the
result of growth factors or cytokines produced by MAC
cells (Moy et al., 1993). With new modalities like Optical
coherence tomography (OCT), very good correlation is
found between histology and OCT images.
Mohs micrographic surgery (MMS) is the preferred
method for the removal of MAC.
2. Clinical presentation
MAC generally presents as a smooth, yellow or ﬂesh-
colored, slow-growing indurated plaque or cystic nodule,
which develops in 3–5 years. The most common site of
involvement is the head and neck, including the lips
(74%) as shown by the Surveillance, Epidemiology and
End Results (SEER) database analysis of 223 patients
(Fig. 1) (Rustemeyer et al., 2013). MAC can also occur
on other less common locations like the scalp (Rotter
et al., 2003; Lountzis et al., 2007), tongue (Schipperet al., 1995), axilla (Nadiminti et al., 2007; Abbate et al.,
2003; Ban et al., 2003), trunk (Chiller et al., 2000;
Leibovitch et al., 2005; Ohtsuka and Nagamatsu, 2002;
Salerno and Terrill, 2003), upper extremities (Thomas
et al., 2007; Leibovitch et al., 2005; Ohtsuka and
Nagamatsu, 2002; Lei et al., 2000), vulva (Chiller et al.,
2000; Buhl et al., 2001), buttocks (Murata et al., 1997)
and genitals (Callahan et al., 2002). The SEER analysis
also showed that MAC is more common in whites (90%)
(Yu et al., 2010), more common in females than males
(57% vs 43%), more common on the left side (Chiller
et al., 2000) and more common in middle-aged to older
patients. It rarely occurs in children (McAlvany et al.,
1994).
MAC is usually asymptomatic, but if perineural involve-
ment is present, patients may report numbness, paresthesia
or tingling (Friedman et al., 1999). Generally, the tumor is
conﬁned to the skin (75%) according to the SEER data-
base. However, tumor invasion into underlying soft tissue,
muscle and bone is possible, especially since MAC is often
diagnosed at a later stage and has invaded deep into the
dermis or subcutis by the time of diagnosis. In a few num-
ber of patients, metastasis have been reported, namely to
the lymph nodes (Rotter et al., 2003; Ban et al., 2003;
Bier-Lansing et al., 1995; Ohta et al., 2004), mediastinum
(Yugueros et al., 1998) and lungs (Gabillot-Carre et al.,
2006).
The average tumor size at diagnosis in one of the studies
was less than 2 cm in diameter in 80% of patients, between
2 and 2.9 cm in 11% of patients and between 4 and 7.9 cm
in the remaining 11% of patients (Leibovitch et al., 2005).
The time of tumor development before presentation in a
review was found to have been less than 5 years in 75%
Figure 2. Findings in deep slices after complete tumor excision. Small,
solid nests (SN) and cystic structures (CY). Evidence of malignancy is
indicated by inﬁltration of nerves and perineural spaces (PI). Findings led
to the diagnosis of MAC. H&E staining; magniﬁcation 200.
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included 33% of patients presenting with recurrent tumors,
confounding the ability to ﬁnd the rate of development of a
primary lesion (Leibovitch et al., 2005).
The clinical size is diﬃcult to determine because there is
frequently extensive subclinical involvement (Thomas
et al., 2007). Although MAC is slow growing, the tumor
extensively inﬁltrates adjacent tissue, often requiring exci-
sion with signiﬁcantly wider margins than the original sup-
posed defect. MMS is ideal for tracing the subclinical
extension and perineural involvement. The size of the
defect can be up to 6 times the clinical appearance of the
lesion (Thomas et al., 2007). The overall survival rate of
MAC is good and death secondary to it is unlikely,
although it causes high morbidity. The 10-year survival
rate is 10%, which is similar to patients of similar age with-
out MAC (Yu et al., 2010).
3. Etiology
The etiology of MAC is unknown, however, ultraviolet
light and radiation have been implicated in its pathogenesis
(Abbate et al., 2003). Three cases have been associated with
immune suppression: two in renal organ transplant recipi-
ents and one associated with chronic lymphocytic leukemia
(Snow et al., 2001).
4. Histopathology
Histopathologically, MAC is a poorly circumscribed,
deeply inﬁltrative, asymmetric tumor. It has two compo-
nents within the desmoplastic stroma (Goldstein and
Barr, 1982); the upper dermis, which usually contains ker-
atin horn cysts and nests of basaloid cells with follicular
diﬀerentiation and the deeper dermis, which show neoplas-
tic epithelial ‘tadpole-shaped’ ducts with eosinophilic secre-
tions. These ductal structures are surrounded by a deep
pink sclerotic stroma that is often ﬁbrotic and commonly
shows perineural and intramuscular invasion (Friedman
et al., 1999; Wetter and Goldstein, 2008). This suggests that
MACs likely originate from a pluripotent keratinocyte that
diﬀerentiates along both eccrine and folliculosebaceous-
apocrine pathways and this accounts for the biphasic histo-
logical appearance (Goldstein and Barr, 1982; Ongenae
et al., 2001; Lober and Larbig, 1994; Aasi, 2013). The
tumor cells often appear benign with lack of cytologic atyp-
ia, and few if any mitosis (Goldstein and Barr, 1982).
The ability of MACs to diﬀerentiate along multiple
pathways to varying degrees probably makes the interpre-
tation of histological margins and appropriately classifying
the tumor challenging. Misdiagnosis is often secondary to
inadequate sampling (Wetter and Goldstein, 2008) and
because of the bland histological features with little cyto-
logic atypia or mitosis. Perineural invasion is a useful,
though not universal, diagnostic ﬁnding (Friedman et al.,
1999; Wetter and Goldstein, 2008) (Fig. 2) (Rustemeyer
et al., 2013). A suﬃciently deep biopsy with adequate sizehelps guard against misdiagnosis secondary to sampling
error, because architectural features are important in diag-
nosis (see Fig. 3) (Aasi, 2013).
The histologic distinction between MAC and desmo-
plastic trichoepithelioma (DTE) can be challenging, espe-
cially in the setting of a superﬁcial biopsy. Thus, the
distinction between these neoplasms is important in direct-
ing appropriate patient management. The standard of care
for MAC is wide local excision, while on the other hand,
the standard of care for DTE is much more conservative.
DTE is a tumor which frequently occurs on the cheek of
a young person, therefore wide local excision is not cosmet-
ically favorable. Histologically, it is a well-circumscribed
tumor in the superﬁcial and mid dermis with cords and
nests of basaloid cells within a ﬁbrous stroma. Speciﬁc fea-
tures like foci of dystrophic calciﬁcation, keratinous cysts,
and keratin granulomas are found.5. Immunohistochemistry
Immunohistochemistry can help distinguish MAC from
other tumors, and highlights eccrine and pilar diﬀerentia-
tion (Friedman et al., 1999). Carcinoembryonic antigen
(CEA), epithelial membrane antigen (EMA), and cytoker-
atin stains are the most reliable. CEA has been the marker
of choice in demonstrating ductal diﬀerentiation in MAC.
Broad-spectrum antikeratin antibodies (AE1/AE3)
strongly stain epithelial cells in MAC. EMA stains ductal
structures (Aasi, 2013; Nagatsuka et al., 2006). Various
markers have been proposed to help diﬀerentiate MACs
from other histological mimics. However, caution should
be exercised when interpreting immunohistochemical
results as no single stain has proven absolutely reliable in
Histological Features of MAC:
• Malignant.
• Eccrine differentiation. 
• Plate-like growth pattern within the reticular dermis. 
• Infiltrates deep into the subcutaneous fat and/or skeletal muscle. 
• Pleomorphism and mitotic figures may be prominent in some cases. 
• Psuedohorn cysts with laminated keratin may be present in the superficial portion. 
• Alternating islands and strands of basaloid and epithelioid cells with variable ductal differentiation and 
calcification.
• Neoplastic aggregates are larger superficially and diminish in size in deeper tissue. 
• Some aggregates are ductal in nature with luminal centers that are lined by a pink cuticle. 
• Cords and strands may be very thin and can sometimes be comprised of just one cell layer. 
• Dense hyalinized stroma consisting of thickened bundles surround the neoplastic aggregates. 
• Perineural invasion is a characteristic feature. 
• Adnexal structures are diminished or destroyed where the tumor is present. 
Figure 3. List of the histological features of MAC.
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et al., 1999; Wick et al., 1990; Costache et al., 2008).
There is no useful immunostain reported in the distinc-
tion of MAC versus DTE (Yamamoto, 2002; Vidal et al.,
2010). However, in a comparative study, CK19 was found
to be a potential helpful marker in separating MAC from
DTE, although with one setback because one-third of
MAC cases seem to be negative for CK19. CK19 has been
shown to express diﬀerentially, in which a malignant trans-
formation is typically paralleled by an increased CK19
expression. Although there are more CK19-positive MAC
than DTE cases, there is no correlation between increased
CK19 expression (Miettinen et al., 1997) and clinical
outcome.6. Other modalities
Newer diagnostic techniques include using Optical coher-
ence tomography (OCT). It is a non-invasive, real-time,
cross-sectional technique that is usable for prompt diagnosis
before surgery and in particular for therapeutic monitoring
and marginal mapping of skin cancer in vivo (Alawi et al.,
2013). MAC shows characteristic criteria on OCT, which
are divided into superﬁcial and sub-epidermal ﬁndings.
The superﬁcial layer shows irregular, uneven, but smooth
surface with no skin appendages. The sub-epidermal layers,
however, show large, round, regular structures with an alter-
nation of hyper- and hypo-refractivity, resulting in an
onion-like appearance, which corresponds to keratin cysts.
Excellent correlation between OCT images and histology
was found, however other diﬀerential diagnoses have to be
considered (Wetter and Goldstein, 2008).7. Diﬀerential diagnosis
Diﬀerential diagnosis on histopathology is similar to the
clinical diﬀerential diagnosis (Goldstein and Barr, 1982),and one must be aware of other malignant or benign
processes that can also show elements of eccrine or pilar
diﬀerentiation. It includes DTE, syringoma, trichoade-
noma, morpheaform basal cell carcinoma, squamous cell
carcinoma, and metastatic breast carcinoma (Leibovitch
et al., 2005).
MAC can resemble syringoma in a superﬁcial biopsy,
but asymmetry, single-cell strands, and perineural and
intramuscular invasion diﬀerentiate MAC from a syrin-
goma, which tends to be symmetric, circular, and well-cir-
cumscribed. There are no immunohistochemical markers
to diﬀerentiate them. DTE usually has a less developed
ductal growth pattern, which diﬀerentiates it from MAC
and it often contains at least rudimentary papillary mes-
enchymal bodies, and frequently has stromal calciﬁcations.
Syringomatous carcinoma is another variant of MAC
that may be distinguished histologically by a more basaloid
appearance with prominent dermal sclerosis, but its clinical
appearance and behavior are equivalent (Hu, 2006).8. Management
Surgical modalities are most deﬁnitive in the treatment
of MACs. It can grow undiagnosed for years because of
the subtle clinical ﬁndings and banal appearance histolog-
ically. Understanding that the tumor is distinguished by
widespread inﬁltration along indistinct boundaries empha-
sizes the need for comprehensive margin examination
during removal.
Currently, most primary tumors are treated with wide
local excision (87% of cases in the SEER database), with
10.8% of cases treated with Mohs micrographic surgery
(Yu et al., 2010). Incompletely excised lesions will recur.
With conventional excision, recurrence rates may be as
high as 47% within the ﬁrst 3 years (Friedman et al.,
1999), while on the other hand, recurrence rates for
Mohs surgery range from 0% to 22% with a 5-year
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Palamaras et al., 2010).
In a prospective study of 44 cases treated by Mohs sur-
gery, tumor recurrence rate was found to be 5% with a 5-
year follow-up and those recurrent tumors referred for
treatment with Mohs surgery needed more stages to clear,
were more likely to have perineural invasion and had larger
postoperative defects (Leibovitch et al., 2005). Tumors are
more likely to recur if the tumor at initial presentation was
recurrent rather than primary (Thomas et al., 2007).
In another retrospective study of 48 cases, defects after
Mohs surgery were found to be four times larger than
the clinically evident tumors and an average of 2.6 stages
were needed to clear the tumor. Also, 30% of patients
who had conventional excision of the tumor had positive
margins and needed additional surgeries. No patients trea-
ted with Mohs surgery needed more procedures. Thus,
clear margins and fewer procedures were noted in the
Mohs treatment group. Both groups experienced complica-
tion rates (Chiller et al., 2000).
Immunostains can be used to delineate histologicmargins
during Mohs surgery. They tend to work especially well on
frozen sections since the target antigen is preserved in tissue
processing, but unfortunately they are time-consuming and
costly. Some special stains are especially useful in banal-ap-
pearing tumors, speciﬁcally if signiﬁcant inﬂammation is
present to mask the tumor cells. Special stains include
CEA, AE1/AE3, and EMA which all stain positive and
others likeCK20which stains negative (Thosani et al., 2008).
Slow Mohs are staged excisions that are done on paraf-
ﬁn sections to improve tumor detection. The surgeon sends
a ﬁnal layer for paraﬃn embedding to enhance margin con-
trol. This makes it easier to interpret than frozen sections,
but this method is slower (Friedman et al., 1999; Barlow
et al., 1996). A retrospective study of 9 cases found that
recurrence in periocular tumors with involvement of deep
ocular fat or perineural involvement, could have arguably
been prevented had an additional layer been submitted
for permanent sectioning (Palamaras et al., 2010).
Toluidine blue staining helps detect subtle tumor islands
in MACs. It is a rapid staining technique that stains tumor
stroma pink and identiﬁes mucopolysaccharides like hya-
luronic acid (Humphreys et al., 1996). It is easy to use in
conjunction with frozen sections. There are many small
nests and clusters of tumor cells that can be easily missed.
Thus, toluidine blue stains the stroma metachromatically
highlighting the small nests or strands of cells and perineu-
ral involvement (Wang et al., 2007).
Long-term follow up is necessary in patients with MAC.
Some cases of local recurrence have been reported as long
as 30 years after initial treatment (Lupton and McMarlin,
1986). In rare occasions, the tumor is inoperable, because
of large size or involvement of vital structures.
Other treatment modalities include chemotherapy and
radiotherapy. Chemotherapy might be useful in patients
with widespread disease who have no other treatment
options, but it is not ﬁrst-line treatment (Eisen, 2005).Reports of radiotherapy in treatment of MAC are incon-
clusive. It might even convert the tumor to a more aggres-
sive undiﬀerentiated form (Stein et al., 2003).Conﬂict of interest
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